Donepezil and Dermatitis - atopic - a phase IV clinical study of FDA data

Summary:

Dermatitis - atopic is reported as a side effect among people who take Donepezil (donepezil hydrochloride), especially for people who are female, 60+ old, have been taking the drug for 1 - 2 years also take Dupixent, and have Dementia alzheimer's type.

The phase IV clinical study analyzes which people have Dermatitis - atopic when taking Donepezil. It is created by eHealthMe based on reports of 24,262 people who have side effects when taking Donepezil from the FDA, and is updated regularly.

What is Donepezil?

Donepezil has active ingredients of donepezil hydrochloride. It is often used in dementia. eHealthMe is studying from 24,564 Donepezil users. Check the latest studies of Donepezil.

What is Dermatitis - atopic?

Dermatitis - atopic (inflammatory, chronically relapsing, non-contagious and pruritic skin disorder) is found to be associated with 2,008 drugs and 1,972 conditions by eHealthMe. Check the latest studies of Dermatitis - atopic.

On Jul, 15, 2026

24,262 people reported to have side effects when taking Donepezil.
Among them, 21 people (0.09%) have Dermatitis - atopic.

Could Donepezil cause Dermatitis - atopic?

Among these 21 people:

How long have people been on Donepezil when they have Dermatitis - atopic? *

What is the gender of people who have Dermatitis - atopic when taking Donepezil? *

female: 63.16 %
male: 36.84 %

What is the age of people who have Dermatitis - atopic when taking Donepezil? *

What are other drugs people take besides Donepezil? *

Dupixent: 4 people, 19.05%
Alendronic Acid: 3 people, 14.29%
Amlodipine: 3 people, 14.29%
Hydroxyzine: 3 people, 14.29%
Ubrelvy: 3 people, 14.29%
Botox: 3 people, 14.29%
Paracetamol: 3 people, 14.29%
Risperidone: 3 people, 14.29%
Duloxetine Hydrochloride: 3 people, 14.29%
Xyzal: 1 person, 4.76%

What are other side effects people have besides Dermatitis - atopic? *

Itching: 5 people, 23.81%
Visual Impairment: 3 people, 14.29%
Neurodermatitis (a skin disorder characterized by long lasting itching and scratching): 3 people, 14.29%
Skin Fissures (a crack in the skin): 3 people, 14.29%
Skin Exfoliation (removal of the oldest dead skin cells): 2 people, 9.52%
Blister (small pocket of fluid within the upper layers of the skin caused by forceful rubbing (friction), burning, freezing, chemical exposure): 2 people, 9.52%
Conjunctivitis (pink eye): 2 people, 9.52%
Appetite - Decreased (decreased appetite occurs when you have a reduced desire to eat): 2 people, 9.52%
Middle Insomnia (difficulty returning to sleep after awakening either in the middle of the night): 2 people, 9.52%
Headache (pain in head): 1 person, 4.76%

What are the existing conditions these people have? *

Dementia Alzheimer's Type (loss of mental ability with alzheimer's symptom): 4 people, 19.05%
Dermatitis (inflammation of the skin resulting from direct irritation by an external agent or an allergic reaction to it): 3 people, 14.29%
Hyperlipidaemia (presence of excess lipids in the blood): 2 people, 9.52%
Diabetes: 2 people, 9.52%
Urinary Incontinence (inability to control the flow of urine and involuntary urination): 1 person, 4.76%
Type 2 Diabetes: 1 person, 4.76%
Rectal Cancer (cancer of rectum): 1 person, 4.76%
Psychotic Disorder: 1 person, 4.76%
Pneumonia: 1 person, 4.76%
Narcolepsy (brain's inability to regulate sleep-wake cycles normally): 1 person, 4.76%

* Approximation only. Some reports may have incomplete information.

Do you take Donepezil and have Dermatitis - atopic?

- Check whether Dermatitis - atopic is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Donepezil:

Donepezil (24,564 reports)

Browse all side effects of Donepezil:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Dermatitis - atopic:

Dermatitis - atopic (2,008 drugs)

Browse all the conditions that are associated with Dermatitis - atopic:

Dermatitis - atopic (1,972 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on donepezil hydrochloride (the active ingredients of Donepezil) and Donepezil (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.